A twice-yearly injection of Lenacapavir offers a 96% reduced risk of infection overall, making the injection significantly more effective than the daily oral PrEP...
Gilead Sciences signed licensing agreements with six generic manufacturers to increase access to lenacapavir for HIV prevention. But no, it will still not be...